Organoplatinum Compounds
"Organoplatinum Compounds" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Organic compounds which contain platinum as an integral part of the molecule.
Descriptor ID |
D009944
|
MeSH Number(s) |
D02.691.800
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Organoplatinum Compounds".
Below are MeSH descriptors whose meaning is more specific than "Organoplatinum Compounds".
This graph shows the total number of publications written about "Organoplatinum Compounds" by people in this website by year, and whether "Organoplatinum Compounds" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
Year | Major Topic | Minor Topic | Total |
---|
1987 | 2 | 0 | 2 | 1989 | 0 | 1 | 1 | 1990 | 0 | 1 | 1 | 1992 | 1 | 0 | 1 | 1997 | 0 | 1 | 1 | 1999 | 0 | 1 | 1 | 2001 | 1 | 1 | 2 | 2002 | 0 | 1 | 1 | 2003 | 2 | 0 | 2 | 2004 | 1 | 2 | 3 | 2005 | 2 | 1 | 3 | 2006 | 3 | 1 | 4 | 2007 | 1 | 1 | 2 | 2008 | 0 | 1 | 1 | 2009 | 0 | 1 | 1 | 2010 | 0 | 3 | 3 | 2011 | 2 | 2 | 4 | 2012 | 1 | 1 | 2 | 2013 | 0 | 5 | 5 | 2014 | 0 | 5 | 5 | 2015 | 1 | 2 | 3 | 2016 | 0 | 4 | 4 | 2017 | 1 | 4 | 5 | 2018 | 0 | 2 | 2 | 2019 | 0 | 1 | 1 | 2020 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Organoplatinum Compounds" by people in Profiles.
-
Innocenti F, Sibley AB, Patil SA, Etheridge AS, Jiang C, Ou FS, Howell SD, Plummer SJ, Casey G, Bertagnolli MM, McLeod HL, Auman JT, Blanke CD, Furukawa Y, Venook AP, Kubo M, Lenz HJ, Parker JS, Ratain MJ, Owzar K. Genomic Analysis of Germline Variation Associated with Survival of Patients with Colorectal Cancer Treated with Chemotherapy Plus Biologics in CALGB/SWOG 80405 (Alliance). Clin Cancer Res. 2021 01 01; 27(1):267-275.
-
Rosenberg JE, O'Donnell PH, Balar AV, McGregor BA, Heath EI, Yu EY, Galsky MD, Hahn NM, Gartner EM, Pinelli JM, Liang SY, Melhem-Bertrandt A, Petrylak DP. Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy. J Clin Oncol. 2019 10 10; 37(29):2592-2600.
-
Catenacci DV, Tesfaye A, Tejani M, Cheung E, Eisenberg P, Scott AJ, Eng C, Hnatyszyn J, Marina N, Powers J, Wainberg Z. Bemarituzumab with modified FOLFOX6 for advanced FGFR2-positive gastroesophageal cancer: FIGHT Phase III study design. Future Oncol. 2019 Jun; 15(18):2073-2082.
-
Marco MR, Zhou L, Patil S, Marcet JE, Varma MG, Oommen S, Cataldo PA, Hunt SR, Kumar A, Herzig DO, Fichera A, Polite BN, Hyman NH, Ternent CA, Stamos MJ, Pigazzi A, Dietz D, Yakunina Y, Pelossof R, Garcia-Aguilar J. Consolidation mFOLFOX6 Chemotherapy After Chemoradiotherapy Improves Survival in Patients With Locally Advanced Rectal Cancer: Final Results of a Multicenter Phase II Trial. Dis Colon Rectum. 2018 Oct; 61(10):1146-1155.
-
Maron SB, Alpert L, Kwak HA, Lomnicki S, Chase L, Xu D, O'Day E, Nagy RJ, Lanman RB, Cecchi F, Hembrough T, Schrock A, Hart J, Xiao SY, Setia N, Catenacci DVT. Targeted Therapies for Targeted Populations: Anti-EGFR Treatment for EGFR-Amplified Gastroesophageal Adenocarcinoma. Cancer Discov. 2018 06; 8(6):696-713.
-
de W Marsh R, Talamonti MS, Baker MS, Posner M, Roggin K, Matthews J, Catenacci D, Kozloff M, Polite B, Britto M, Wang C, Kindler H. Primary systemic therapy in resectable pancreatic ductal adenocarcinoma using mFOLFIRINOX: A pilot study. J Surg Oncol. 2018 Mar; 117(3):354-362.
-
Liauw SL. A Pancreatic Predicament. Int J Radiat Oncol Biol Phys. 2017 10 01; 99(2):296-297.
-
Venook AP, Niedzwiecki D, Lenz HJ, Innocenti F, Fruth B, Meyerhardt JA, Schrag D, Greene C, O'Neil BH, Atkins JN, Berry S, Polite BN, O'Reilly EM, Goldberg RM, Hochster HS, Schilsky RL, Bertagnolli MM, El-Khoueiry AB, Watson P, Benson AB, Mulkerin DL, Mayer RJ, Blanke C. Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial. JAMA. 2017 06 20; 317(23):2392-2401.
-
Eng OS, Dumitra S, O'Leary M, Wakabayashi M, Dellinger TH, Han ES, Lee SJ, Benjamin Paz I, Singh G, Lee B. Base Excess as a Predictor of Complications in Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy. Ann Surg Oncol. 2017 Sep; 24(9):2707-2711.
-
Oshima G, Guo N, He C, Stack ME, Poon C, Uppal A, Wightman SC, Parekh A, Skowron KB, Posner MC, Lin W, Khodarev NN, Weichselbaum RR. In Vivo Delivery and Therapeutic Effects of a MicroRNA on Colorectal Liver Metastases. Mol Ther. 2017 07 05; 25(7):1588-1595.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|